Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone972-390-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$152.45 million
Profitability
Miscellaneous
Employees570
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Atrion (NASDAQ:ATRI) Frequently Asked Questions
What is Atrion's stock symbol?
Atrion trades on the NASDAQ under the ticker symbol "ATRI."
How often does Atrion pay dividends? What is the dividend yield for Atrion?
Atrion announced a quarterly dividend on Wednesday, May 22nd. Investors of record on Friday, June 14th will be paid a dividend of $1.35 per share on Friday, June 28th. This represents a $5.40 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, June 13th. View Atrion's Dividend History.
How were Atrion's earnings last quarter?
Atrion Co. (NASDAQ:ATRI) issued its quarterly earnings data on Wednesday, May, 8th. The medical instruments supplier reported $5.07 EPS for the quarter. The medical instruments supplier had revenue of $41.61 million for the quarter. Atrion had a return on equity of 16.89% and a net margin of 22.76%. View Atrion's Earnings History.
When is Atrion's next earnings date?
Has Atrion been receiving favorable news coverage?
Media stories about ATRI stock have trended somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atrion earned a news impact score of -1.0 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Atrion.
Are investors shorting Atrion?
Atrion saw a decrease in short interest in May. As of May 15th, there was short interest totalling 31,300 shares, a decrease of 12.3% from the April 15th total of 35,700 shares. Based on an average daily volume of 6,300 shares, the days-to-cover ratio is currently 5.0 days. Currently, 2.2% of the company's shares are short sold. View Atrion's Current Options Chain.
Who are some of Atrion's key competitors?
Some companies that are related to Atrion include Haemonetics (HAE), Penumbra (PEN), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Merit Medical Systems (MMSI), Cantel Medical (CMD), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Nevro (NVRO), Shockwave Medical (SWAV) and Mazor Robotics (MZOR).
What other stocks do shareholders of Atrion own?
Who are Atrion's key executives?
Atrion's management team includes the folowing people:
- Mr. Emile A. Battat, Exec. Chairman (Age 81)
- Mr. David A. Battat, Pres & CEO (Age 49)
- Mr. Jeffery Strickland, VP, CFO, Treasurer & Sec. (Age 60)
Who are Atrion's major shareholders?
Atrion's stock is owned by a number of of institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (7.35%), Kayne Anderson Rudnick Investment Management LLC (7.15%), Kayne Anderson Rudnick Investment Management LLC (4.54%), Pennsylvania Trust Co (3.11%), Royce & Associates LP (1.95%) and BTIM Corp. (0.72%). Company insiders that own Atrion stock include Emile A Battat, Jeffery Strickland and Ronald Nicholas Spaulding. View Institutional Ownership Trends for Atrion.
Which major investors are selling Atrion stock?
ATRI stock was sold by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, THB Asset Management, Rhumbline Advisers, Royce & Associates LP, KAMES CAPITAL plc, SG Americas Securities LLC, Crawford Investment Counsel Inc. and Creative Planning. Company insiders that have sold Atrion company stock in the last year include Jeffery Strickland and Ronald Nicholas Spaulding. View Insider Buying and Selling for Atrion.
Which major investors are buying Atrion stock?
ATRI stock was acquired by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Kayne Anderson Rudnick Investment Management LLC, First Trust Advisors LP, First Trust Advisors LP, Virginia Retirement Systems ET AL, Grisanti Capital Management LLC, Martingale Asset Management L P and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Atrion.
How do I buy shares of Atrion?
Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atrion's stock price today?
One share of ATRI stock can currently be purchased for approximately $901.00.
How big of a company is Atrion?
What is Atrion's official website?
How can I contact Atrion?
Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at 972-390-9800 or via email at [email protected]
MarketBeat Community Rating for Atrion (NASDAQ ATRI)
MarketBeat's community ratings are surveys of what our community members think about Atrion and other stocks. Vote "Outperform" if you believe ATRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
